Breast cancer
Breast cancer is one of the most common malignant tumors in women, with an incidence rate of 7-10% of all malignant tumors in the body, second only to uterine cancer in women, and has become a major cause of threat to women's health. Its onset is often related to genetics, and the incidence rate is higher in women between the ages of 40 and 60, before and after menopause. It is one of the most common malignant tumors that usually occurs in breast glandular epithelial tissue, seriously affecting women's physical and mental health and even endangering their lives. Breast cancer in men is rare, with only about 1-2% of breast patients being male.
-
Site of disease:
breast -
Infectious :
Not contagious -
Frequent population:
Women aged 45-55, late menopause, over... -
Related symptoms:
Breast lumps Distant metastasis of breast cancer A palpable lump deep in the areola Swelling of axillary lymph nodes A peanut-sized lump on the lateral edge of the pectoralis major -
Concurrent disease:
Related Drugs
Vinorelbine tartrate
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Manufacturer:
Guangzhou Hanfang Pharmaceutical Company Limited
Vinorelbine tartrate
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphoma, etc.
Vinorelbine tartrate injection
Indication: It is clinically used for non-small cell lung cancer, metastatic breast cancer, advanced ovarian cancer, malignant lymphadenopathy, etc.
Manufacturer:
Qilu Pharmaceutical (Hainan) Co., Ltd.
Exemestane Tablets
Indication: It is indicated for postmenopausal patients with advanced breast cancer whose disease has progressed after treatment with tamoxifen.
Exemestane Tablets
Indication: It is indicated for postmenopausal patients with advanced breast cancer whose disease has progressed after treatment with tamoxifen.
Manufacturer:
Tongfang Pharmaceutical Group Co., Ltd.
Exemestane Tablets
Indication: It is indicated for postmenopausal patients with advanced breast cancer whose disease has progressed after treatment with tamoxifen.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Hainan Zhuotai Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Shanxi Zhendong Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Chengdu Beite Denuo Pharmaceutical Co., Ltd.
Related Ingredients